Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Great news hot off the press for ABAT:
http://seekingalpha.com/article/303735-harbin-electric-buyout-approved-implications-for-u-s-listed-chinese-stocks?ifp=0&source=email_global_markets
This should be the beginning of the end for short attacks on China stocks like ABAT !!! And a beginning of a search for oversold stocks in the China sector like ABAT that are not frauds!!!
Where there is one, there are two,....and so on to many!!!! The same logic the shorts used to throw all China stocks into a tail spin a year ago!!!!
CSGH fell farther because it rallied farther.
Not good news for any China stock investor.
Most of the info you need is in the last 14 months of posts on the MNLU site.
There were not enough shorts at the bottom left to amount to a hill of beans. And AEXP had ZERO shorts. This has been real buyers, that sold on the way down from $1+ over a 6 month wait for $$ news and for flooding in Miss to abate earlier this year, trying to get back in before the rally tops out. A little less than 5% of the total shares issued have traded so far in this rally in either of the two merging companies, so it has to legs to run!!! So it may have a lot of upside left, a lot more than most of expected.
The real longs, have held onto at least 95% of the outstanding shares of both companies since the rally started 10 days ago.
Click here for a larger view:
http://investorshub.advfn.com/uimage/uploads/2011/10/31/ljpdsfidelity-compare-chart.img.gif
Comparison of the two stocks over time.
I think it is time we put the pig out of its misery. Let's push this stock up to $1/share where it belongs tomorrow!
Go MNLU !!!!
I did not understand your shorts question, sorry. Naked shorts have 3 days to cover (IIRC, but it is more complex for MMs and brokers), borrowed shares (borrowed by shorts to sell) pay a rental fee to hold (stay short) as long as they want.
The stock is down with the market, plus the last 2 news cycles, one is that the CFO/director resigned (news today, resigned for [personal reasons, possibly health?), and the other is the vehicle subsidiary took out a loan. I think they took out the loan in vehicle subsidiary to fund receivables and volume growth in sales )based on prior news), and to show that a China bank would lend them 7-8 million US dollars, but I think some shorts jumped on the news first.
Things are going to get real busy in here this week. I am offering to be an assistant MOD if we need one?
Lots of news popping up all over the place on this one tonight!!!
http://seekingalpha.com/article/303614-beacon-power-becomes-second-doe-loan-winner-to-declare-bankruptcy?ifp=0&source=email_alternative_energy_investing
http://www.bizjournals.com/boston/news/2011/10/31/beacon-power-declares-bankruptcy.html?ana=yfcpc&kme=Email
http://www.bizjournals.com/boston/news/2011/10/31/feds-defend-beacon-power-loans.html?ana=yfcpc&kme=Email
http://www.bizjournals.com/boston/news/2011/10/31/boston-law-firm-is-top-bcon-creditor.html?ana=yfcpc&kme=Email
My contention is that it no longer matters who the auditor is, if it is a China stock with shares traded in the US, it is suspect no matter who the auditor is. And changing auditors or officers, just makes it that more suspect by most investors that lack a strong stomach, at least until the new auditor is done, which seems to take a year or more!
For me, I am now down, wiped out by four US tech investments since 2008, and all of my China tech investments are still holding up reasonably well all considered (I was careful to buy them cheap). Today's falling star for me was BCON. They filled for BK today. They had the only Flywheel energy storage system (large scale backed by the US DOE) on the market. After the 40 million dollar DOE loan, and the start up of the NY 20 megawatt plant, it seemed like the time to invest there. Luckily I only tasted that apple (LOL, the NY Apple, LOL). Now wishing I had put the money here.
LOL, I been smelling roastpig for a week now!!!! GO MNLU !!!!!
Thanks for the all clear signal to PIG out and buy at .40 like crazy !!!!!
A voice from the PAST, from pigroast11:
Tuesday, October 04, 2011 6:32:58 PM
Re: Ecomike post# 4875
Post # of 5160
Double down? You should really stop telling people to buy this garbage. I tried to warn everyone @ .39 to get out and everyone laughed. Now i'm telling you once again its going to ZERO. Sell any rally
pigroast11
Wednesday, October 05, 2011 3:38:22 PM
Re: Ecomike post# 4889
Post # of 5160
This company wont exist in 2-3 years.
You will own worthless paper certs.
Member Profile pigroast11
Friday, September 30, 2011 6:36:49 PM
Re: AntiMarketMaker post# 4860
Post # of 5160
Same bag holders that were buying @ .30 and .39
Hows that working out for you? I'll cover @ .001
Member Profile pigroast11
Friday, September 30, 2011 12:31:20 PM
Re: maybe_this_time post# 4851
Post # of 5160
Why would anyone buy this garbage!?
When CGYV switched auditors the stock price dropped about 80% while everyone waited for Deloitte to do the annual reports (they immediately, once hired, refused to use the prior 2 years audits as the basis for the current year), and the stock nose dived, while Deloitte took nearly a year to come out with a report that said opps, the prior 2 years were better not worse, sorry mr. investor.
I will not hold a stock that begins the process of changing or even discussing changing auditors just to say "look I have a top 4 audit". Also top four auditors are no long the answer, just look at the ones that Deloitte bailed on recently!!! Like Longtop, CCME,
http://www.nytimes.com/2011/05/27/business/27norris.html?pagewanted=all
http://af.reuters.com/article/commoditiesNews/idAFL3E7LD2O820111013
http://digicha.com/index.php/2011/05/longtop-teaches-deloitte-how-to-discover-a-chinese-stock-fraud-again/
In each of those three cases — Longtop, China MediaExpress and ShengdaTech — the auditors discovered discrepancies, but only after signing off on financial statements. That was not the case in this year’s other — and perhaps most embarrassing — resignation by a Big Four auditing firm.
In December, KPMG was retained by China Integrated Energy, which claimed to be a leader in the production of biodiesel. Just hiring a Big Four auditor enabled it to raise $24 million from institutional investors in the United States. Three months later, KPMG certified the financials.
Six weeks after that, KPMG repudiated the report and resigned. By then, China Integrated Energy executives had refused to cooperate with a board investigation into claims that the company was a complete fraud.
A chance yes, but at what value (?) I have no idea. I was lucky in that I never bought enough shares (at $3, post R/S value, 2010) to really hurt me bad, and now the price is too low to sell, they are not worth selling, too few dollars left on the table (risk reward favors me holding now), so I may ride this one out. If it drops another 50% at the open tomorrow I may even double, or triple down for a short term trade, or bounce.
It will all depend on how much unsecured debt they had, and whether the court will swap out secured debt for stock with the DOE and US Treasury?
One thing is for sure, something of it will survive just keep the DOE from taking a 100% loss on the operating plant!!!!
They had about 70 employees doing sales (LOL) and R&D plus an overpaid CEO, so there is plenty of room to cut costs!!!!!
90% of the time, BK will wipe out all existing common shares. But there have been a few recent exceptions the last 3 years, but I suspect that will go back towards the norm of most wiping out the old common. Even YRCW's recent hail-mary pass did a 99% dilution of the common shareholders, while replacing most old debt with 99% new shares, where 48 million shares went to 4.8 billion (1:100 dilution) shares to wipe out a lot of old debt. Of course the company is worth more with out that debt, but it has yet to post a profit (it might post a profit with the debt gone now?).
One good thing is the low share count!
Right now it is more of a short term gamble, that anything else. I find it interesting that it is not already selling at .02/share!!!!
Nice buying volume today, almost 4 million shares. Hopefully a sign the tide has changed? Almost no chat here, meaning the bottom may be in.
More detailed news clip on today's news:
CytRx Announces Favorable Initial Results from its Ongoing Phase 1b/2 Clinical Trial in Patients with Soft Tissue Sarcomas
BY Business Wire
— 8:30 AM ET 10/31/2011
LOS ANGELES--(BUSINESS WIRE)-- CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced favorable response and safety indications from a group of patients with advanced solid tumors (principally soft tissue sarcomas) in the Company’s ongoing Phase 1b/2 clinical trial with INNO-206, its tumor-targeting conjugate of the commonly used chemotherapeutic agent doxorubicin. Patients in this portion of the Phase 1b/2 clinical trial received three different dose levels of INNO-206 to determine its maximum tolerated dose.
In the initial Phase 1b portion of the clinical trial, 12 patients, primarily with advanced soft tissue sarcomas, have received one or more administrations of treatment with INNO-206 in three-week cycles. The Company determined a maximum tolerated dose of INNO-206 that delivers a doxorubicin equivalent of 3½ times the standard doxorubicin dose administered to sarcoma patients. CytRx is currently enrolling additional patients who will be treated at that dose to gather further response data in parallel with the planned international Phase 2b clinical trial scheduled to start this quarter.
Of five patients who have completed four cycles with INNO-206 at the maximum tolerated dose, one patient has exhibited a partial tumor response (greater than 30% tumor shrinkage) and four patients have stable disease. Unexpectedly, a large, painful oral sarcoma that caused difficulty eating in one patient was greatly reduced following a single INNO-206 treatment. Common side effects reported to date from the Phase 1b/2 trial include low neutrophil (white blood cell) and platelet counts, minor mouth ulcers and mild nausea, which are expected side effects of doxorubicin.
“Initial data of response and safety from INNO-206 in this portion of the Phase 1b/2 trial are very important,” said CytRx President and CEO Steven A. Kriegsman. “Although these initial results are from a limited number of patients, the individuals treated were very advanced in their disease and had previously received multiple different chemotherapy agents, including doxorubicin, so we are pleasantly surprised to observe stable disease, much less tumor shrinkage, in these cancer patients. We believe these early indications bode well for the potential success of our international Phase 2b clinical trial in patients who have advanced disease but were not previously administered chemotherapy.”
“The response from this small group of patients treated with INNO-206 is encouraging and we look forward to sharing the full, final data from the Phase 1b/2 clinical trial in a presentation at ASCO 2012,” said Sant P. Chawla, M.D., F.R.A.C.P. The Phase 1b/2 clinical trial is being conducted at the Sarcoma Oncology Center in Santa Monica, Calif. under the direction of Dr. Chawla, a world-renowned expert in soft tissue sarcoma treatment who has evaluated most chemotherapies being tested in this indication.
In September 2011, CytRx announced completion of the maximum tolerated dose portion of the Phase 1b/2 trial, which included 12 patients. The patients from the early portion of the trial were evaluated for tumor response after four cycles of INNO-206. The Company also announced plans to add 12 patients to the Phase 1b/2 trial to receive INNO-206 at the maximum tolerated dose, and six of those additional patients have already been enrolled.
About INNO-206
INNO-206 is a novel conjugate of doxorubicin that binds covalently to albumin, the most abundant protein in blood plasma, and is circulated throughout the body. Doxorubicin is a standard chemotherapeutic treatment for a variety of cancers and is used either alone or in combination with other chemotherapy agents. INNO-206 is designed with a linker that releases doxorubicin in the low pH environment of tumors, concentrating the chemotherapeutic agent where it preferentially damages the tumor while minimizing the effect on healthy tissues. This conjugate formulation has the potential to safely deliver greater amounts of doxorubicin directly to the tumor compared with standard doxorubicin treatment, which could lead to improved efficacy.
CytRx holds the exclusive worldwide rights to INNO-206 -- a platform technology designed to reduce adverse events by controlling drug release and preferentially targeting tumors. In addition to doxorubicin, several other chemotherapy agents have been attached to the linker used for INNO-206, including paclitaxel, cisplatin and methotrexate, and may be incorporated into future clinical development by the Company.
About Advanced Soft Tissue Sarcomas
Patients with advanced soft tissue sarcomas who can no longer be treated with surgery have a poor prognosis and limited options. Progression-free survival for patients with advanced soft tissue sarcomas is around six to seven months, and median overall survival is approximately 18 months with less than one-third of these patients living past three years. Combinations of the chemotherapy drugs ifosfamide and doxorubicin appear to offer the highest response rates and longest time to progression in these patients; however, these regimens have not significantly improved survival and are quite toxic.
About CytRx Corporation
CytRx Corporation is a biopharmaceutical research and development oncology company engaged in the development of high-value human therapeutics. The CytRx oncology pipeline includes three programs in clinical development for cancer indications: INNO-206, tamibarotene and bafetinib. With its tumor-targeted doxorubicin conjugate INNO-206, CytRx ( plans to initiate a Phase 2b clinical trial as a treatment for soft tissue sarcomas in 2011, following its Phase 1b/2 clinical trial. The Company is evaluating bafetinib in the ENABLE Phase 2 clinical trial in high-risk B-cell chronic lymphocytic leukemia (B-CLL) and the PROACT Phase 2 clinical trial in advanced prostate cancer. CytRx's pipeline also includes tamibarotene, which it is testing in a double-blind, placebo-controlled Phase 2 clinical trial in patients with non-small-cell lung cancer, and which is in a registration clinical trial as a treatment for acute promyelocytic leukemia (APL). For more information on the Company, visit http://www.cytrx.com.
Nearly 1/3 of the entire shares issued have traded today at an average of about .13, so someone has bought up 1/3 of the company for about .13/share. That values the company at 3.8 million dollars, but the SEC filling showed a 30 million dollar spread between assets and debts (if that number is right?). Shareholders equity was listed as 29 million dollars, in the latest 10-Q. That is $1.00/share in shareholders equity remaining. Which begs the question "Why did they file BK?" in the first place???? Since they were down to 5 million in cash at the end of June, my guess is they ran out of cash and could not sell convertible debt to hose shareholders with again, and could not borrow against the assets. So the current stock price is 10% of the stockholders equity, which is mostly plants and equipment. My guess is they could sell the equity part of the assets for 10 cents on the dollar, but will they get full value for the debt part of the assets. If the sell the assets in full for 50% discount, the stock holders get nothing.
So it all hinges on the BK plan, and how many buyers line up to buy the remains, or if BCON can walk away from a lot of debt, and take one more run at it?
Then why hasn't that worked for other firms that switched auditors to one of the top four firms? Show me one (or 2 or 3 please) case(s) where it has worked!!! The one China firm I know of that did what you suggest is down 70% the last 6 months (in spite of record revenue and profits), and was down 85% for 18 months after the agreed to switch to Deloitte, a top 4 firm, while Deloitte piddled with the audit, and Deloitte increased the reported revenue and sales in the restated annual of prior years. If you do not believe me, read the 3 year history on CGYV.
This could get interesting folks! They just may stiff one company with the debt, let it go BK, and save the other ship (let one sink, and leave one floating?).
Doubt I would put my faith in either company, or executive at this point, but if they float Terra as a separate company, that splits the value into two public stocks. Current shares works out to about 141 million shares COIN, and market cap would be 1/2 of prior ( 1.5 million listed on Fidelity).
Not sure if the annual sales (3.63 million dollars) are representative based on the last 2 quarters, or if they include some of the ex-NJ facility sales (which is no longer), or last Terra sale ($1 million dollars late last year?) from last year?), sales the last 12 months. But the market cap (based on .01/share) is now less than sales.
If you split the 2 companies you have each one being bought with a market 1/2 of the MC today (1.5 million based on .01/share). I suspect the plan is float Terra as public entity, get the share price way up first (R/S #2 down the road), sell convertible debt, and then if the company fails again, convert and dump the new Terra shares.
The CEOs (Waste water guy, Ed, and The Terra guy) and their bloated $1 million dollar salary still needs to go for this POS to ever make money and grow organically, and Terra needs a business plan and sales that will work, which they do not have yet.
I am watching the fall out I predicted, but no soon enough :(, from a safe distance right now. If this gets to .001 I just might take a small position.
The problem is not the auditing firms or choice of auditing firms, the problem is differences in US and China regulations that are in conflict over China secrecy requirements (Laws prohibiting certain disclosures that the SEC has asked some China firms to disclose, but such disclosure would violate China law... but note that CSGH has not been accused by anyone of faking anything, nor is the SEC investigating CSGH) and differences in the two counties accounting practices, some of which have to do with differences in tax practices, good will valuation, derivative valuations (like changing warrant liabilities), and so on.
Like I have said here before, CYTR is sitting on some blockbuster drugs!!! Every PR I have read in the last 18 months or more on the drug trial results from CYTR has had huge positive (some surprisingly more positive them hoped for) results, and here is one more today!!!
Of five patients who have completed four cycles with INNO-206 at the maximum tolerated dose, one patient has exhibited a partial tumor response (greater than 30% tumor shrinkage) and four patients have stable disease. Unexpectedly, a large, painful oral sarcoma that caused difficulty eating in one patient was greatly reduced following a single INNO-206 treatment.
Maybe China will buy the remains, and start making them. One thing that is different from the corn ethanol massacre and the Solar BK(s) (I am expecting more solar stocks to go belly up) is that BCON was the only player in the large flywheel arena, so someone may want to buy the remains, but with no serious sales or revenue, I still expect the senior secured creditors to wipe out the common, unless they want to a YRCW and have sheep left to sell more dilution shares in a debt to new common conversion.
I will probably sell at the open, and then watch the funeral process.
Good luck with that. I tried that with the corn ethanol stocks when they went under in 08-09, never made a dime. Only rally will be small at about .02 from short covering. I did not expect BK this soon! Sure glad I never averaged down on this one!!!! I think cheap natural gas, and managements inability to control cash burn, and sell systems killed this one. They had way too much overhead for way too long. I bought the press last year that they would turn earnings positive when the NY plant was running. What a BF lie that was!!!!
Sad to say it, but I have gotten more burned on US Tech stocks going BK, than China Tech stocks, in spite of all the fear mongering short articles about China stocks!!!!!
Nuts! Not sure which is worse, BK, or being diluted to worthlessness. Same result, but at least this way I won't be tempted to average down. The fall out from this may be entertaining? From what I read last week the Solendra BK was caused by Germany's huge cut back in buying solar panels, and China dumping the glut on the US market, knocking the solar cell prices down 70-80%!!!!
My guess is JCI will buy it all at a junk sale at the court back door soon. Sad!
May be a lot of year end tax loss selling here on lower volume near the holidays, combined with convertible share dumping, still might see .01/share before it bottoms, then add in a R/S someday, and even the .05 sounds expensive to me. What matters is the Market cap which is final share count times price per share. I doubt the market cap should be higher than 100 million dollars until they turn a profit again.
The long term MACD divergence at the low prices is what got my attention (true sign of bottom forming) when everyone was running for the sidelines thinking the world was about to end in September, both on the major indexes and MNLU.
Thanks for the chart!!!! Nice to see the falling knives I bought back up and shining, LOL!
Minor correction, he was not an is not on the BOD, he was appointed to the "advisory board" (which I take to mean a different committee), and he accepted, just to keep the details straight.
Not that it really matters considering his credentials are what started this explosive rally, off a bottom where most had considered the company near death.
Perhaps Cameleon Corporation would be a better name choice here on the next iteration of name changes for GSRE? I copied this from the 2009 financial report for GSRE.
The company was originally organized under the name
Sierra Gold Corporation on August 26, 1988. Articles
of amendment changing the name of the company to
PayForView.com Corporation with filed with the state
of Nevada on April 6, 200; articles of amendment
changing the name of the company to PayForView Media
Group Holdings Corporation were filed with the state
of Nevada on April 23, 2003; articles of amendment
changing the name of the company to James Barclay
Alan, Inc., were filed with the state of Nevada on
October 14, 2003; articles of amendment changing the
name of the company to Titan Consolidated, Inc., were
filed with the state of Nevada on January 21, 2005;
articles of amendment changing the name of the company
to Titan Oil and Gas, Inc., were filed with the state
of Nevada on February 2, 2006; articles of amendment
changing the name of the company to Green Star
Energies, Inc., were filed with the state of Nevada on
October 15, 2008.
It is based on the ease with which we passed several resistance levels, on the lack of huge volume, and the fact that we closed above the last resistance level, with the next resistance level at .40 to .50 (more of a range where I expect it to trade next, range where it traded on the way up last time, and range where it had support last time, going back 2 years). We have not even hit a 1 million share day yet.
I don't think there was substantial shorting left when the rally began. I think this has been 99% real buyers.
The private offering I mentioned again earlier today, had some restricted warrants at .40 and .50, with 6 and 12 month life spans (very short times)IIRC, so that is another reason I expect to see that target range hit. If it gets to .60/share this coming week then something really major is going on, buyout or JV must be underway (and far less dilution than expected!!!), or there is just an unexpected irrational feeding frenzy that got out of control, LOL!!!! If it gets to .50, I expect that .40 will be defended!!!
Good reminder of why we are invested here in MVTG:
http://news.ino.com/headlines/?newsid=689817738567791
Researchers who survey the lobster population in Long Island Sound say they are seeing the fewest number of the crustaceans since they started trawling in the 1980s.
Connecticut state fisheries biologist Penny Howell says the abundance of lobsters has been falling "precipitously" since a devastating die-off in 1999 and there is no sign of a turnaround.
Nick Crismale (KRIS-mah-lee) of Guilford, head of the Connecticut Commercial Lobstermen's Association, says there are only about 30 full-time lobstermen left in the state, down from more than 300 in the late 1990s. He says he turned to clamming this year because it did not make financial sense to put out lobster traps.
Rising water temperatures and runoff contamination are among the factors blamed for the population decline.
Also it seems that major manufacturing dislocations are happening with companies like Toyota again in Asia, not from and earthquake/Tsunamis this time, but from record flooding in Thailand and Bangkok:
http://www.telegraph.co.uk/news/worldnews/asia/thailand/8857442/Warning-of-neck-deep-floods-in-Thailands-capital.html
http://photoblog.msnbc.msn.com/_news/2011/10/29/8537459-thais-use-improvised-rafts-to-float-around-in-flooded-bangkok
http://newley.com/2011/10/29/thailand-flooding-update-october-29-2011-bangkoks-flood-defenses-hold/
Keep a look out for a 10-Q in November, where they should finally reveal how bad the recent dilution was, by finally telling us what price the last $600,000 share lot sold for per share!!! My guess is we will gap down hard on that news.
I was not referring to shorts, shorting CSGH. I was referring to the big name writers (Muddy Waters, CitronResearch, to name a few) that have attacked the larger cap, high priced stocks in the China sector, like Longtop, DEER, APWR, and the entire sector as a whole in the process.
I have no problem with their current auditor, but if they change auditors I will sell immediately on that news, as it will be bad news, not good news as you seem to think.
The stock hitting a new low this past week or so, while most others rallied hard, is enough to chart a path to 10 cents (or something near there) if year end tax loss selling hits on a down day in December, on low volume.
One of the things that makes it profitable to be in stocks, is that the market can be extremely irrational in bear and bull markets, for a long time. But sooner of later, they correct. I will be delighted to grab all the cheap CSGH shares I can if it goes low enough, as I am in this one for the long haul back $1/share
Been playing catch up reading here today. Have not followed this one for several months, but it does not look good from reading the last 30 posts. Are their any new lessons you all learned here the last 3 months that I might have missed by not reading all xxx gazzilon posts?
Regarding the post I am replying to, note that in the US, it takes a unanimous jury vote to win a criminal trial (which is very hard to get), and criminal jury's do not award $$ damages to investors as far as I know. It is very hard to send a corporation to jail, or to execute one, LOL!
Secondly, it is almost impossible to prove "Intent"
As far as the SEC, Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001)
What were the terms of your ask at .185? #shares offered? Any limits on the order?
Who is the broker you placed the order with?
I noticed slow penny stock posting of new orders on Thursday, and my broker (Fidelity) had bad data all day on at least one of my other penny oil stocks that traded all day (IHUB data worked, but Fidelity data was a day old all day, and never updated, (it was frozen), so I past it off as overloaded systems and overloaded MMs on the big weeks rally world wide.
Usually when the MM's like Nite back off the top spot of bid and ask, they have decided to let the market make itself, rather than risk getting run over by a pack of bulldozers by trying to pick up pennies in front of a moving dozer!!!! LOL
I seriously doubt any share dumping at retail is possible here, not by MNLU, based on my DD pouring over the last 2 years of SEC filings by AEXP and MNLU, and they had many opportunities to dump shares in the last 18 months, but chose not to do so, even when MNLU was well over $1/share this year. MNLU and the merger seems to preclude it as well. They had a private offer out already for restricted shares over a month ago, 66 million at .15/share, that failed to get fully subscribed (as we never got news of it's being fully subscribed, which would have solved their need for cash to complete the wells, pay the outstanding bills, and tie the well to the nearby pipeline. Real people that dumped on the way down the last 9 nine months have been buying back on the chance that the private offer to raise cash is being replaced with a JV deal lead by the new guy we heard about 8 days ago.
Lastly, NITE did the same thing (they backed off the bid and ask) when MNLU rallied last time from about .25 to well over $1/share, when there was no share dumping, while they drilled the BP#1 well about 9-12 months ago.
I think so, but it has expired about 5-6 times already, and been renewed each time for 2-3 months with an SEC update, so it is not a concern, but it will bring fresh PR press and SEC updates when the merger deadline is extended, yet again.
Looks to me like, with a little luck, we may get the chance to pick up more all time low cheap CSGH shares here by year end (maybe as cheap as .10/share?), perhaps when late year tax loss selling hits on a down day. I am gathering dry powder to add to my longs when that day comes. I am buying to hold long term for 2-3 years or more, maybe longer if the clouds over China stocks clears by then.
I also expect to see one last round of short article attacks on China stocks as the deadlines for audited annual reports arrives for most of them in March to May 2012. China stocks seem to have a hard time meeting US deadlines for annual reports as a group, and that seems to draw out mr. shorty, just as the spring rallies end and selling starts going into the summer. But they may be too cheap, under $1/share for shorts to bother with next year, in which case they may not get attacked again.
When the new China lithium iron polymer phosphate production plants are completed and go on line by year end (like ABAT's and CBAK's new plants being built right now, and note they are CSGH customers of the LiFePO4 material that CSGH has built a new plant for), and start shipping the new generation of large LiFePO4 polymer batteries for use in hybrid buses, and other large heavy duty road vehicles, the sales and profits on CSGH (who is supplying them with the raw materials) should spike nicely, and show up next spring in the quarterly reports. I plan to be a lot longer on share counts on all three stocks by then, especially CSGH.
He is saying that level II bids were piling up (the real market,real buyers, thus the "something was up message) and the MM's (the manipulator market makers, brokers...) had to cover their shorts fast.
When a stock gets as oversold as MNLU was, and real buyers show back up in volume, the shorts must scramble to buy to cover their shorts, thus a bidding war starts and the price runs up to its target very fast. The next target is .40 to .50 now. Good chance we will see it early next week before any serious correction gets a chance to take hold based on the stocks strength today.
IFUS is a real sleeper!!! I agree with you: "I truly believe that Mark and Joe are on to something here and am confident they will expand their markets in the upcoming months. "
While I have run across that issue many times in my work and life (dead food, LOL), I still go back to a graduate study class in biochemcial engineering I took where we had to use simple heat to sterilize a bioreactor batch product of B-12 vitamin, before finally purifying (filtering out the solids and so on) it, and we ended up with a complex problem in mixing and heat transport as the B-12 was permanently denatured (made worthless) by the heat just about as fast as the living organisms in the bioreactor were killed by the heat. We had to optimize heat transport rate, heat and cooling, to save the remaining B-12, and yet get a 100% sterile kill.
Made me finally realize that all the vitamins in my fresh raw veggies were dead and gone if I cooked (boiled) the food first!!!
4-6000 years ago mankind ate all his food raw, just like wild animals do. Cooking and preserving food became the new habit of a wandering race that needed food in the winter.....Then in the days of Pasteur, we decided all bacteria are bad and went on a cooking and purifying frenzy that has led to many new, previously unheard of diseases.
That is why I am such of fan of alternatives like IFUS supplement products to put certain nutrients back into our diets!!! And one of the novelties about IFUS products is the rebalancing of the digestive system so it can capture and hold onto nutrients we need so badly, and help us keep the proper flora of the digestive system in balance. Try to work day to day with a screwed up digestive track, it is like trying to drive on the freeway with four flat tires! LOL
A friend of mine had a cat diagnosed with diabetes about 10 years ago. Another friend of mine put the cat on a strict diet of raw meat (fresh, like sushi), and the cat went from nearly dead, getting huge insulin shots 2-3 times a day, to healthy with no signs of diabetes in 8 weeks!!! The vet was shocked!
These are some of the reasons I am invested here in IFUS, and not just in biotech drugs stocks.
Today was even more bizzaro! Some one sold a little under 300 shares at .06, for the entire days volume (Big block sale, LOL!), then the ask moved up from .20 to .25!!! LOL I am guessing someone is desperate to generate volume here, MM perhaps.
You know, every once in a while we get into a debate here (over IFUS) about FDA approved prescription only drugs, versus food supplements (like IFUS markets) and the credibility, or lack thereof, of products that came out of FDA drug trials, versus supplements that had no FDA trials.
But I got to thinking, most things we buy, like TVs, computers, cell phones, cars, and so on, also never went through FDA, or similar government trials or approvals!!! Yet no one is trying to claim that my laptop I am typing this on, is suedo science snake oil because it does not have the US Government stamp of approval.
Many products that made it through FDA trials and approvals are now widely advertised on TV now as having caused serious side effects for which law firms are now widely advertising day and night on national TV about the nasty side effects and how to sue the big drug firms for damages....Like birth defects from taking Zoloft!
In the end, placebo trials do not seem to be all they are cracked up to be, based on the flood of TV ads I see for lawsuits. How you feel after taking the product for years is all an end user cares about in the end, quality of life. If we went by the idea that any product that did not go through FDA trials was dangerous snake oil, I wonder what we would eat for breakfast, lunch and dinner? Genetically modified Monsanto crops perhaps? LOL
Also, many biotechs that have no sellable products yet, and no revenues, have market caps of 100 million dollars and higher, while IFUS has selling products being sold and repeatedly bought by happy customers already and a lowly market cap of only about 200,000 to 300,000 dollars.
Another new high, near the close!! .265, we must be headed straight back to .40/.45, old support.
We have bounced up 3 times off of .23, which is looking like support now.